Research and Publications:
Mr. Rosen is an independent consultant and serves on the board of directors of AcelRx, Inc., Alcobra, Ltd. (Chairman since 2014), Entrega, Inc., and Kala Pharmaceuticals, Inc. He has been serving as interim CEO of AcelRx since April 1, 2015. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. From 1994 to 2004, Mr. Rosen served ALZA Corporation in a number of executive positions, including president. Mr. Rosen previously served on a number of public and private company board of directors including Pearl Therapeutics, Inc., where he served as interim president and CEO from June 2010 to March 2011. He is a lecturer in the Department of Chemical Engineering at Stanford University and a lecturer in Management at the Stanford Graduate School of Business (GSB). Mr. Rosen received an M.B.A. from the Stanford GSB and an M.S. and B.S. in Chemical Engineering from MIT and Stanford, respectively. He is a member of the National Academy of Engineering.